Iomeprol 

Melting point: 263-265°C

Boiling point: 813.2±65.0°C (Predicted)

Density: d420 1.166; d437 1.161; d420 1.334; d437 1.329; d420 1.446; d437 1.441

Refractive index: nD20 1.3828; nD20 1.4327; nD20 1.4660

Storage conditions: -20°C Freezer

Solubility: Slightly soluble in DMSO, slightly soluble in methanol

Acidity coefficient (pKa): 11.36±0.46 (Predicted)

Form: Solid

Color: White to off-white

Cell experiment

Solubility in H₂O: 125 mg/mL (160.86 mM; ultrasonic-assisted dissolution required)

Solubility in DMSO: 100 mg/mL (128.69 mM; ultrasonic-assisted dissolution required; note that hygroscopic DMSO significantly affects product solubility, recommend using newly opened DMSO)

Preparing Stock Solutions：

Please select an appropriate solvent to prepare the stock solution based on the solubility of the product in different solvents. After preparation, aliquot and store the solution to avoid product failure caused by repeated freeze-thaw cycles.

Storage conditions and duration of stock solution: -80°C for 6 months; -20°C for 1 month. When stored at -80°C, use within 6 months; when stored at -20°C, use within 1 month.

Note: If water is selected as the solvent for the stock solution, please dilute to the working concentration and sterilize by filtration through a 0.22 μm filter before use.

The degree of radiographic enhancement by iomeprol is related to the iodine concentration in the tissue of interest following the administration of iomeprol. However, the exposure-response relationships and time course of pharmacodynamic response of iomeprol have not been fully characterized.At therapeutic concentrations, iomeprol was not shown to cause significant effects on the cardiovascular, central nervous, renal, and complement systems.

omeprol is a radiographic iodinated contrast agent that opacifies the vessels and body structures where the contrast agent is present following intravenous or intra-arterial administration, permitting radiographic visualization of the internal structures through attenuation of X-ray photons. In imaging of the body, iodinated contrast agents diffuse from the vessels into the extravascular space. In normal brain with an intact blood-brain barrier, the contrast agent does not diffuse into the extravascular space and contrast enhancement is generally due to the presence of contrast within the vascular space. In patients with a disrupted blood-brain barrier, the contrast agent accumulates in the extravascular space in the region of disruption.